MRC enters the final days of April with one story dominating the tape — a persistent insider accumulation campaign that has run for six weeks and shows no sign of stopping.
Sime Armoyan, a declared 10% shareholder, has bought Morguard shares on at least ten separate occasions since mid-March, accumulating roughly 11,900 shares at prices clustered around CAD 114.75–115.00. The 90-day net insider position totals approximately 30,900 shares at a net cost of around CAD 2.6 million. The consistency of the buying — spanning volatile market sessions in late March and early April — is the most notable signal on this name right now. These are not token purchases. They are repeated, methodical additions at a price well below the stock's current close of CAD 119.50.
The short side tells a deliberately quiet story. Short interest is barely below 1% of the free float, at roughly 0.996%, and has drifted only modestly — up about 1.8% on the week in share terms, but the absolute level is too low to carry much analytical weight. Borrow conditions reinforce that picture: cost to borrow has collapsed to just 0.61%, down from a brief spike above 2.7% in early April, and availability in the lending pool remains loose. There is no meaningful squeeze dynamic at work, and no evidence of a building short thesis. The ORTEX short score of 49.6 sits almost exactly at the midpoint of the 0-100 range — a neutral read with negligible drift over the past ten days.
Ownership concentration is worth flagging as context. Kuldip Sahi holds roughly 63% of the company. G2S2 Capital — the vehicle associated with the Armoyan family — holds a further 13%. Combined, those two holders account for more than three-quarters of all shares outstanding. That extreme concentration is both a structural feature and a practical constraint: the free float is small, average volumes are thin, and price discovery can be idiosyncratic. The institutional register beyond those two anchors is modest — GAMCO, Letko Brosseau, and Dimensional each hold sub-1% positions, all essentially unchanged in recent filings.
On the valuation front, the analyst data is too stale to act on — the most recent price target of CAD 145.00 was filed as of late February 2026 and reflects no analyst changes since. The mean target implies meaningful upside to current levels, but without fresher coverage activity, it is a datapoint to note rather than a signal to trade. The dividend history is similarly dated; no dividend has been recorded since mid-2022, so yield-driven buyers have had little to work with.
Earnings reactions have been subdued. The two most recent prints produced next-day moves of under 1.5% in either direction, with five-day drifts barely larger. For a stock this thinly traded, that muted post-earnings behaviour is consistent with the low short interest and the low availability of offsetting hedges.
What to watch next: whether Armoyan's buying continues above the CAD 115 entry level now that the stock has appreciated to CAD 119.50, and whether any analyst re-engages with fresh coverage to close the gap on the outstanding price target.
See the live data behind this article on ORTEX.
Open MRC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
